Media & Press
-
Sodium Bicarbonate US Supply Agreement
Phebra has entered into a commercial agreement to supply Sodium Bicarbonate Injection to the US to assist with a shortage in the US hospital market.
January 2017
-
Phebra Welcomes PBS Listing for Leukaemia Treatment
Phebra has welcomed the listing on the Australian PBS of its PHENASEN® (arsenic trioxide) Injection for the first line treatment of newly-diagnosed acute promyelocytic leukaemia (APL).
April 2016
-
Clinical Trial for Jellyfish Sting Antidote
Phebra is supporting a new clinical trial to test the efficacy of Magnesium Sulphate as an antidote for Irukandji Syndrome (IS), the acute pain caused by certain jellyfish stings.
January 2015
-
Manufacturing and Product Supply Underway at New Phebra Plant
Phebra’s manufacturing and product supply from its new sterile manufacturing plant is underway.
February 2014
-
Australian Distribution of Syntometrine
Phebra announces an agreement with Alliance Pharma to supply Syntometrine to the Australian market.
September 2013
-
Phebra’s New Energy Efficiency Program
Phebra is ‘going green’ and implementing an energy efficiency program at the new manufacturing plant.
June 2013
-
New Phebra Plant receives TGA manufacturing licence
Phebra welcomes the granting of its licence from the TGA for its new sterile manufacturing plant
May 2013
-
Industry and Innovation Minister Greg Combet Opens New Phebra Pharmaceutical Plant
Federal Minister for Industry and Innovation, Greg Combet, officially opened and inspected Phebra’s new sterile manufacturing plant.
March 2013
-
Phebra commences validation manufacturing at new plant
The first stage of validation manufacturing at Phebra’s new plant begins
December 2012
-
Phebra welcomes PBS listing of Naproxen
Naproxen suspension is approved for reinbursement through the Pharmaceutical Benefits Scheme (PBS)
November 2012